Gain Therapeutics (GANX) announced the presentation of a poster at the 36th EORTC-NCI-AACR, ENA, Symposium on molecular targets and cancer therapeutics that details the use of the Company’s Magellan drug discovery platform to identify allosteric inhibitors targeting discoidin domain receptor 2, DDR2. ENA 2024 is being held October 23-25 in Barcelona, Spain. The poster, “Identification of allosteric inhibitors targeting Discoidin Domain Receptor 2,” which was presented on-site on October 23, detailed how the 3D structure of DDR2 guided a high-throughput virtual screening and subsequent experimental validation that resulted in GT-03842 and additional analogue compounds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GANX:
- Gain Therapeutics to present at MJFF’s Annual Parkinson’s Disease Conference
- Gain Therapeutics Excels in Neurodegenerative Drug Trials
- Gain Therapeutics presents preclinical data on GT-02287
- Gain Therapeutics presents Phase 1 GT-02287 data
- Gain Therapeutics to present preclinical data on GT-02287 at Neuroscience 2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
